首页>
外国专利>
NEW GALENIC FORM FOR ORAL ADMINISTRATION OF PROLONGED MOLSIDOMINE LIBERATION
NEW GALENIC FORM FOR ORAL ADMINISTRATION OF PROLONGED MOLSIDOMINE LIBERATION
展开▼
机译:新的加莱尼克语形式,用于长期进行猛烈解放的口腔管理
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention relates to a novel sustained-release oral galenical form of molsidomine for the treatment of all forms of angina attack (angina of effort, spastic angina, mixed angina). According to the invention, this novel galenical form contains a therapeutically effective amount of molsidomine or one of its active metabolites and has an in vitro dissolution rate [measured spectrophotometrically at 286 or 311 nm by the method described in the European Pharmacopoeia, 3rd edition (or USP XXIV), at 50 rpm, in 500 ml of a 0.1 N HCl medium, at 37° C.] of: 15 to 25% of molsidomine released after 1 hour, 20 to 35% of molsidomine released after 2 hours, 50 to 65% of molsidomine released after 6 hours, 75 to 95% of molsidomine released after 12 hours, 85% of molsidomine released after 18 hours and 90% of molsidomine released after 24 hours, the plasma peak of molsidomine obtained in vivo occurring 2.5 to 5 hours, preferably 3 to 4 hours, following the administration of said form, and having a value of between 25 and 40 ng/ml of plasma. Application: therapeutics industry.
展开▼